Table 4.
Univariate HRs for predictors of MSIs and SIs in the entire BSPAR‐ETN cohorta
| Predictors | MSIs, HR (95% CI) | SIs, HR (95% CI) |
|---|---|---|
| Sex | ||
| Male | Reference | Reference |
| Female | 1.04 (0.72–1.51) | 1.11 (0.64–1.91) |
| Age at baseline | 0.91 (0.88–0.95) b | 0.90 (0.85–0.96)b |
| Disease duration at baseline | 0.97 (0.92–1.02) | 1.00 (0.93–1.08) |
| JIA at baseline | ||
| Nonsystemic | Reference | Reference |
| Systemic | 2.14 (1.41–3.25) b | 2.57 (1.46–4.54)b |
| Oral corticosteroid use at baseline | 2.11 (1.49–3.00) b | 2.13 (1.29–3.51)† |
| MTX use at baseline | 1.80 (1.22–2.66) b | 1.90 (1.06–3.40) |
| C‐HAQ score at baseline | 1.23 (0.89–1.69) | 1.26 (0.80–1.99) |
| JADAS‐71 at baseline | 1.01 (0.99–1.02) | 1.01 (0.99–1.04) |
| No. of comorbid conditions at baseline | ||
| 0 | Reference | Reference |
| 1 | 1.23 (0.80–1.88) | 1.29 (0.70–2.40) |
| ≥2 | 1.66 (1.06–2.58) b | 1.88 (1.01–3.50)b |
a
HRs = hazard ratios; MSIs = medically significant infections; SIs = serious infections; BSPAR‐ETN = British
Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study; 95% CI = 95% confidence interval; JIA = juvenile idiopathic arthritis; MTX = methotrexate; C‐HAQ = Childhood Health Assessment Questionnaire; JADAS‐71 = Juvenile Arthritis Disease Activity Score in 71 joints.
b
P < 0.05.